http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Arshad Hussain Wazir,Qudratullah Khan,Nisar Ahmad,Faizan Ullah,Imdadullah Quereshi,Hazrat Ali 한국재료학회 2022 한국재료학회지 Vol.32 No.2
Copper nanoparticles (CuNPs) are considered of great importance due to their high catalytic and antimicrobial activities. This study focuses on the preparation and characterization of CuNPs, and on their antibacterial/antifungal activities. A copper salt (copper sulfate pentahydrate) as precursor, starch as stabilizing agent, and ascorbic acid as reducing agent were used to fabricate CuNPs. The resulting product was characterized via different techniques such as X-ray diffractrometry (XRD), Fourier Transform Infrared (FTIR) spectroscopy, and Scanning electron microscopy (SEM) to confirm its characteristic properties. Employing the Scherrer formula, the mean crystallite sizes of copper (Cu) and cuprous oxide (Cu2O) nanocrystals were found to be 29.21 and 25.33 nm, respectively, as measured from the main X-ray diffraction peaks. The functional groups present in the resulting CuNPs were confirmed by FTIR. In addition, the engineered CuNPs showed antibacterial and antifungal activity against tested pathogenic bacterial and fungal strains.
Alam, Sazid,Alam, MD Anzar,Quamri, MA,Sofi, Ghulamuddin,Khan, Mohd. Qudratullah,Ansari, Shabnam Cellmed Orthocellular Medicine and Pharmaceutical 2020 셀메드 (CellMed) Vol.10 No.1
Aim:'Itrifal-e-Sagheer', a compound Unani formulation has been indicated in disease conditions simulating dyslipidemia. The present study was done to substantiate the efficacy of 'Itrifal-e-Sagheer' in dyslipidemia on scientific parameters. Materials and methods: A randomized, single blind, controlled, clinical trial was carried out on 30 patients of dyslipidemia who were randomly allocated into test (n = 15) or control (n = 15) groups. The test drug, Itrifal-e-Sagheer and control drug, Abana® were given to respective group for 45 days along with lifestyle modification. Results: The test drug significantly alleviated the symptoms of subjective parameters (palpitation, breathlessness and weight gain) (p<0.05). There was statistically significant reduction in lipid profile of the patients in test group (p<0.05) than control drug treatment. Conclusion: The study evidenced that Itrifal-e-Sagheer is potentially effective and safe in the treatment of dyslipidemia. However, a multicentric study with robust study design is required to generalize the results.